1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction
Authors: UUSINARKAUS KARI T. , RODBARD HELENA W. , GAAL LUC VAN , WILDING JOHN P. , HANSEN THOMAS , SANDBERG ANNA , TADAYON SAYEH , DAVIES MELANIE J. 
Published: June 2019

Semaglutide, a glucagon-like peptide-1 analog for the once-weekly treatment of type 2 diabetes, provided superior glycemic control and weight loss (WL) vs. comparators in the SUSTAIN clinical trial program. This post hoc analysis assessed if WL was associated with patient-reported health-related quality of life (HRQoL) and treatment satisfaction improvements in SUSTAIN 2-5 and 7. Data for both semaglutide doses (0.5 and 1.0 mg) were pooled across trials (N=2,808). Change in HRQoL (Short Form-36 Health Survey version 2® [SF-36v2®] Physical Component Summary [PCS] and Mental Component Summary) and treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire status version) scores were evaluated in subjects who achieved ≥5% and ≥10% WL vs. those who did not at end of treatment (30, 40 or 56 weeks). Overall, 51.0% and 17.4% of subjects achieved ≥5% and ≥10% WL with semaglutide. Significantly greater improvements in the overall PCS score and most of its components were reported in subjects achieving ≥5% and ≥10% WL vs. those not achieving these responses (Table). WL responses also correlated with overall treatment satisfaction and perception of hyperglycemia (Table).

In conclusion, semaglutide-induced WL was associated with improvements in PCS domains of the SF-36v2®, overall treatment satisfaction and perception of hyperglycemia across the SUSTAIN 2-5 and 7 trials.

Disclosure

K.T. Uusinarkaus: Advisory Panel; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Speaker's Bureau; Self; Amarin Corporation, Amgen Inc., Regeneron Pharmaceuticals, Sanofi US. Stock/Shareholder; Self; Abbott, AbbVie Inc., Amarin Corporation, Pfizer Inc. H.W. Rodbard: Advisory Panel; Self; Bayer US, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi. Consultant; Spouse/Partner; Eli Lilly and Company. Consultant; Self; Gan & Lee Pharmaceuticals. Research Support; Self; Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. Speaker's Bureau; Self; Merck & Co., Inc., Novo Nordisk Inc. L. Van Gaal: Advisory Panel; Self; Janssen Pharmaceuticals, Inc., Johnson & Johnson. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Servier. J.P. Wilding: Consultant; Self; Astellas Pharma Europe Ltd., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, NAPP Pharmaceuticals Limited, Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Novo Nordisk A/S. Speaker's Bureau; Self; Eli Lilly and Company, WebMD. T. Hansen: None. A. Sandberg: Employee; Self; Novo Nordisk A/S. S. Tadayon: Employee; Self; Novo Nordisk A/S. M.J. Davies: Advisory Panel; Self; Eli Lilly and Company, Janssen Global Services, LLC., Novo Nordisk A/S, Sanofi-Aventis, Servier. Research Support; Self; Boehringer Ingelheim International GmbH, Novo Nordisk Foundation. Speaker's Bureau; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk A/S, Sanofi-Aventis, Takeda Pharmaceutical Company Limited.

Funding

Novo Nordisk A/S